Bei Akademie registrieren
Vertex Pharma, US92532F1003

Vertex Pharmaceuticals stock eyes FDA date after RAINIER data

Published on 10/30/2026 at 17:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Vertex Pharmaceuticals stock is heading toward a November FDA decision after positive kidney data. The regulatory date remains the next major catalyst.

FDA date keeps kidney pipeline in focus

  • Vertex said the Phase 3 RAINIER study met its primary and secondary endpoints in IgA nephropathy.
  • The FDA has set November 30, 2026, as the PDUFA target action date for potential accelerated approval of povetacicept.
  • Final RAINIER analysis will assess kidney-function outcomes through Week 104.
Vertex Pharma, US92532F1003, Illustration mit AI erstellt.
Vertex Pharma, US92532F1003, Illustration mit AI erstellt.

Vertex Pharmaceuticals is approaching a regulatory checkpoint for povetacicept after the company reported positive interim results from the Phase 3 RAINIER study in IgA nephropathy on October 23. The results were published in the New England Journal of Medicine and presented at the American Society of Nephrology Kidney Week 2026.

Vertex said RAINIER met its primary endpoint, with povetacicept reducing proteinuria by 52.0% from baseline at Week 36 and by 49.8% versus placebo. The study also met both secondary endpoints. The company reported that 42.2% of treated participants reached a 24-hour urine protein-to-creatinine ratio below 0.5 grams per gram, compared with 6.2% on placebo.

The Vertex Pharmaceuticals release said the FDA has accepted the biologics license application for accelerated approval. The PDUFA target action date is November 30, 2026.

What has changed since our last report

The latest quote is 1.34% above the EUR 493.50 level cited in the most recent relevant report published earlier on October 30. The move clears the threshold for this second main-values edition, while the clinical and regulatory milestones remain the central company-specific factors.

The real-time quote of Vertex Pharmaceuticals stock traded at EUR 500.10 on Lang & Schwarz at 5:03 p.m. CET on Friday, October 30, 2026.

Longer-term kidney data remain important

RAINIER remains blinded until the last patient enrolled completes 104 weeks. The final analysis will use the total estimated glomerular filtration rate slope through Week 104 as its primary endpoint, making longer-term kidney-function data an important follow-up to the interim proteinuria result.

If approved, Vertex plans to offer povetacicept as a low-volume subcutaneous autoinjector administered at home every four weeks. The company is also evaluating patient experience with the device in the PAVANT IgAN study.

The broader U.S. market remains relevant for biotechnology investors; current S&P 500 market reports provide the wider market context.

More company-specific developments are available in more news and analyses on Vertex Pharmaceuticals stock.

Vertex Pharmaceuticals at a glance

  • Company: Vertex Pharmaceuticals Incorporated
  • ISIN: US92532F1003
  • Ticker: VRTX
  • Latest quote: EUR 500.10 on Lang & Schwarz at 5:03 p.m. CET on October 30, 2026
  • Change since prior report: 1.34% above EUR 493.50 at 12:07 p.m. CET on October 30, 2026
  • Regulatory date: FDA PDUFA target action date on November 30, 2026
Disclaimer...
en | US92532F1003 | VERTEX PHARMA | boerse | 70435915 |